🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2024-520387-34-01
Authorised Phase III

A multicentre randomised study on percutaneous stellate ganglion block as first line treatment in patients with electrical storm: the STAR 2 study

2024-520387-34-01 · tracked via the Priya Life Science EU tracker
Sponsor
Fondazione IRCCS Policlinico San Matteo
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Cardiovascular Diseases
Decision date
11/08/2026
Enrollment target
180
Sites
Italy

Condition studied

electrical storm

Investigational medicinal product(s)

Amiodarone Hikma 50 mg/ml soluzione iniettabileLidocaina Kabi 20 mg/ml soluzione iniettabileBUPISEN 5 mg/ml soluzione iniettabile

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

proportion of patients with complete suppression of treated VA (with ATP, internal DC shock or external DC shock) during the first three hours after treatment

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-520387-34-01 on CTIS ↗ ← All trials in the EU